✨ Fexuprazan (CAS 1902954-60-2) | Next-Gen Potassium-Competitive Acid Blocker (P-CAB) for Gastrointestinal Disorders ✨
🧪 Product Overview
Fexuprazan (CAS 1902954-60-2), also known as Abeprazan, is a potassium-competitive acid blocker (P-CAB) with the molecular formula C₁₉H₁₇F₃N₂O₃S and molecular weight 410.41. This high-purity white to off-white crystalline powder (≥95% HPLC) is designed for acid-related gastrointestinal therapies, including erosive esophagitis and peptic ulcer disease. Developed by Daewoong Pharmaceuticals, it offers rapid and sustained acid suppression by inhibiting H+/K+-ATPase, outperforming traditional proton pump inhibitors (PPIs) in symptom relief and mucosal healing.
Key Functions:
Accelerates erosive esophagitis healing and reduces recurrence risk.
Enhances Helicobacter pylori eradication in combination therapies.
Acts as a pharmaceutical intermediate for advanced P-CAB formulations.
Target Industries: Pharmaceutical manufacturing, clinical research, biotechnology.
⭐ Key Advantages
| 🔹 High Purity | 🔹 Rapid Efficacy | 🔹 Dual Action |
|---|
| ≥95% HPLC-certified | Acid suppression within 30 minutes | Combines ulcer healing and H. pylori eradication |
| Batch-specific COA | Superior to PPIs in nocturnal symptom relief | Stable at -20°C for long-term storage |
🏭 Applications
Erosive Esophagitis: Oral formulations for mucosal repair and symptom control.
Peptic Ulcers: Reduces gastric and duodenal ulcer recurrence rates.
H. pylori Therapy: Synergistic use with antibiotics for higher eradication success.
Drug Development: Intermediate for novel P-CAB-based therapies.
📊 Quality Assurance
Testing Standards: Complies with USP/EP pharmacopeial guidelines.
Analytical Methods: Validated via HPLC, NMR, and mass spectrometry.
Packaging: Customizable batches (10mg–1kg) with moisture-proof, light-protected containers.
📈 Market Insights
The global gastroesophageal reflux disease (GERD) therapeutics market is projected to grow at 6.5% CAGR (2025–2030), driven by rising demand for non-PPI therapies. Asia-Pacific leads P-CAB API production, with South Korea and China dominating innovation and cost-efficient manufacturing.
China
